What is Exelixis (EXEL)?
Exelixis is a biotechnology company engaged in the discovery, development, and commercialization of therapies for the treatment of cancer. The company focuses on small molecule drugs that target specific pathways involved in tumor growth and progression. Exelixis employs a research-driven approach to identify novel compounds and advance them through clinical development. Its portfolio includes approved cancer therapies as well as investigational candidates in various stages of development. The company collaborates with academic institutions, pharmaceutical partners, and research organizations to enhance its drug discovery efforts. Exelixis aims to address unmet medical needs in oncology by developing targeted treatments that improve patient outcomes. Its operations encompass research laboratories, clinical development programs, and commercial activities related to oncology therapeutics.
Exelixis Stock Price Today: Live Overview
The price today is shaped by market activity, where Exelixis is noted at $41.40. The price has fluctuated from $40.45 up to $41.54 during the session, marking a change of -0.3154%.
FAQ: Exelixis (EXEL)
What is the current price of EXEL stock?
The current price stands at $41.40.
Does EXEL pay dividends?
Exelixis does not pay dividends.
Does EXEL have a formal corporate presence or regional headquarters in the UAE?
Exelixis operates in the UAE only through partners and distributors without an official regional office or subsidiary.
What is EXEL best known for?
The company is most famous for its oncology-focused biotechnology products.
What assets are typically shown together with EXEL?
Commonly shown alongside EXEL: Yalla Group Limited, Ituran Location and Control Ltd, BioArctic AB
Latest shares articles



